- Home
- NEXT vs HRMY Comparison
NEXT vs HRMY Comparison
Compare NEXT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXT
- HRMY
- Stock Information
- Founded
- NEXT 2010
- HRMY 2017
- Country
- NEXT United States
- HRMY United States
- Employees
- NEXT N/A
- HRMY N/A
- Industry
- NEXT Oil & Gas Production
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- NEXT Energy
- HRMY Health Care
- Exchange
- NEXT Nasdaq
- HRMY Nasdaq
- Market Cap
- NEXT 1.9B
- HRMY 1.6B
- IPO Year
- NEXT N/A
- HRMY 2020
- Fundamental
- Price
- NEXT $7.67
- HRMY $34.05
- Analyst Decision
- NEXT Hold
- HRMY Strong Buy
- Analyst Count
- NEXT 1
- HRMY 8
- Target Price
- NEXT $9.00
- HRMY $52.88
- AVG Volume (30 Days)
- NEXT 1.4M
- HRMY 701.6K
- Earning Date
- NEXT 05-06-2025
- HRMY 05-06-2025
- Dividend Yield
- NEXT N/A
- HRMY N/A
- EPS Growth
- NEXT N/A
- HRMY 13.13
- EPS
- NEXT N/A
- HRMY 2.62
- Revenue
- NEXT N/A
- HRMY $744,852,000.00
- Revenue This Year
- NEXT N/A
- HRMY $20.06
- Revenue Next Year
- NEXT N/A
- HRMY $18.40
- P/E Ratio
- NEXT N/A
- HRMY $13.10
- Revenue Growth
- NEXT N/A
- HRMY 20.62
- 52 Week Low
- NEXT $4.27
- HRMY $26.47
- 52 Week High
- NEXT $9.71
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- NEXT 52.96
- HRMY 69.53
- Support Level
- NEXT $7.17
- HRMY $29.82
- Resistance Level
- NEXT $7.78
- HRMY $30.61
- Average True Range (ATR)
- NEXT 0.34
- HRMY 1.12
- MACD
- NEXT 0.03
- HRMY 0.74
- Stochastic Oscillator
- NEXT 77.44
- HRMY 92.78
About NEXT NextDecade Corporation
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.